Related content

New onset diabetes and atypical antipsychotics

By Liebzeit K.A.   Markowitz J.S.   Caley C.F.  

European Neuropsychopharmacology, Vol. 11, Iss. 1, 2001-02 ,pp. : 25-32

Elsevier

Access to resources Recommend Favorite

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

By Dufour H.   Bondolfi G.   Baumann P.   Seywert F.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 202-202

Elsevier

Access to resources Recommend Favorite

New Atypical Antipsychotics: Experience and Utility in the Elderly

By Sweet R.A.   Pollock B.G.  

Drugs & Aging, Vol. 12, Iss. 2, 1998-02 ,pp. : 115-127

Adis International

Access to resources Recommend Favorite

The new atypical antipsychotics: a review of pharmacoeconomic studies

By Revicki D.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 249-260

Informa Healthcare

Access to resources Recommend Favorite

The new antipsychotics - some pharmacological aspects of their problems and potential

By Reynolds G.P.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 181-185

Informa Healthcare

Access to resources Recommend Favorite